BACKGROUND: We undertook a cost-effectiveness analysis of the Spanish Renal Replacement Therapy (RRT) program for end-stage renal disease patients from a societal perspective. The current Spanish situation was compared with several hypothetical scenarios. METHODS: A Markov chain model was used as a foundation for simulations of the Spanish RRT program in three temporal horizons (5, 10, and 15 years). The current situation (scenario 1) was compared with three different scenarios: increased proportion of overall scheduled (planned) incident patients (scenario 2); constant proportion of overall scheduled incident patients, but increased proportion of scheduled incident patients on peritoneal dialysis (PD), resulting in a lower proportion of scheduled incident patients on hemodialysis (HD) (scenario 3); and increased overall proportion of scheduled incident patients together with increased scheduled incidence of patients on PD (scenario 4). RESULTS: The incremental cost-effectiveness ratios (ICERs) of scenarios 2, 3, and 4, when compared with scenario 1, were estimated to be, respectively, -€83 150, -€354 977, and -€235 886 per incremental quality-adjusted life year (ΔQALY), evidencing both moderate cost savings and slight effectiveness gains. The net health benefits that would accrue to society were estimated to be, respectively, 0.0045, 0.0211, and 0.0219 ΔQALYs considering a willingness-to-pay threshold of €35 000/ΔQALY. CONCLUSIONS: Scenario 1, the current Spanish situation, was dominated by all the proposed scenarios. Interestingly, scenarios 3 and 4 showed the best results in terms of cost-effectiveness. From a cost-effectiveness perspective, an increase in the overall scheduled incidence of RRT, and particularly that of PD, should be promoted.
BACKGROUND: We undertook a cost-effectiveness analysis of the Spanish Renal Replacement Therapy (RRT) program for end-stage renal diseasepatients from a societal perspective. The current Spanish situation was compared with several hypothetical scenarios. METHODS: A Markov chain model was used as a foundation for simulations of the Spanish RRT program in three temporal horizons (5, 10, and 15 years). The current situation (scenario 1) was compared with three different scenarios: increased proportion of overall scheduled (planned) incident patients (scenario 2); constant proportion of overall scheduled incident patients, but increased proportion of scheduled incident patients on peritoneal dialysis (PD), resulting in a lower proportion of scheduled incident patients on hemodialysis (HD) (scenario 3); and increased overall proportion of scheduled incident patients together with increased scheduled incidence of patients on PD (scenario 4). RESULTS: The incremental cost-effectiveness ratios (ICERs) of scenarios 2, 3, and 4, when compared with scenario 1, were estimated to be, respectively, -€83 150, -€354 977, and -€235 886 per incremental quality-adjusted life year (ΔQALY), evidencing both moderate cost savings and slight effectiveness gains. The net health benefits that would accrue to society were estimated to be, respectively, 0.0045, 0.0211, and 0.0219 ΔQALYs considering a willingness-to-pay threshold of €35 000/ΔQALY. CONCLUSIONS: Scenario 1, the current Spanish situation, was dominated by all the proposed scenarios. Interestingly, scenarios 3 and 4 showed the best results in terms of cost-effectiveness. From a cost-effectiveness perspective, an increase in the overall scheduled incidence of RRT, and particularly that of PD, should be promoted.
Authors: J L Górriz; A Sancho; L M Pallardó; M L Amoedo; M Martín; P Sanz; G Barril; R Selgas; M Salgueira; A Palma; M de la Torre; I Ferreras Journal: Nefrologia Date: 2002 Impact factor: 2.033
Authors: Waqar H Kazmi; Gregorio T Obrador; Samina S Khan; Brian J G Pereira; Annamaria T Kausz Journal: Nephrol Dial Transplant Date: 2004-07 Impact factor: 5.992
Authors: F Caravaca; M Arrobas; E Luna; J L Pizarro; C García; J F Espárrago; E Sánchez-Casado Journal: Nefrologia Date: 2003 Nov-Dec Impact factor: 2.033
Authors: E Gallego; A López; I Lorenzo; E López; F Llamas; M L Illescas; E Andrés; A Serrano; E Olivas; C Gómez Roldán Journal: Nefrologia Date: 2003 Impact factor: 2.033
Authors: Ellen Busink; Dana Kendzia; Fatih Kircelli; Sophie Boeger; Jovana Petrovic; Helen Smethurst; Stephen Mitchell; Christian Apel Journal: Eur J Health Econ Date: 2022-06-18
Authors: Luis A Coentrão; Carla S Araújo; Carlos A Ribeiro; Claúdia C Dias; Manuel J Pestana Journal: Perit Dial Int Date: 2013-03-01 Impact factor: 1.756